Klaus Früh, Ph.D.
Credit: OHSU News
Klaus Früh, Ph.D., professor in OHSU’s Vaccine & Gene Therapy Institute, investigates the potential of cytomegalovirus-based vaccines. With colleagues Louis Picker, M.D., and Scott Hansen, Ph.D., both in VGTI, they have found their vaccine platform shows promise as a “shield” against cancer. (OHSU/Christine Torres Hicks)